ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

ACS Approves New Workplaces Intervention Cancer Control Program

April 17, 1992

Advisors suggest NCI establish sarcoma research consortium.

January 30, 2004

CTEP’s Clinical Trials Proposals Reshaped By Discussion: BSC Next On Schedule

May 9, 1986

In Brief: Rhoads Renamed Cancer Advisory Board Chairman; L-B’s Frederick Contract Renewed For $12 Million

June 28, 1974

Cancer Caused By Environmental Exposure “Grossly Underestimated,” Cancer Panel Says.

May 7, 2010

Funding Opportunities Listed (12-page issue).

July 11, 2003